Francois Brisebois
Stock Analyst at Oppenheimer
(2.05)
# 3,057
Out of 5,024 analysts
88
Total ratings
38.64%
Success rate
-5.03%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $7.34 | +8.99% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $3.60 | +66.67% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $13.68 | +485.01% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.53 | +189.33% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.65 | +142.42% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $74.95 | -3.94% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $26.63 | +129.06% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $12.66 | +57.98% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $6.17 | +353.66% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $15.16 | +97.89% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $57.35 | +184.22% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $16.53 | +232.73% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.41 | +963.83% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $7.05 | -14.89% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.18 | +245.91% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $22.59 | -38.03% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.48 | +458.04% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $15.60 | +316.67% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.66 | +76.68% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $6.20 | +2,351.61% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $19.58 | +83.86% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.41 | +14,541.29% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $2.12 | +255,219.15% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.13 | +251.44% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $4.30 | +318.60% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $6.83 | +632.06% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.46 | +221,817.81% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $7.34
Upside: +8.99%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $3.60
Upside: +66.67%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $13.68
Upside: +485.01%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.53
Upside: +189.33%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.65
Upside: +142.42%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $74.95
Upside: -3.94%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $26.63
Upside: +129.06%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $12.66
Upside: +57.98%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $6.17
Upside: +353.66%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $15.16
Upside: +97.89%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $57.35
Upside: +184.22%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $16.53
Upside: +232.73%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $1.41
Upside: +963.83%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $7.05
Upside: -14.89%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.18
Upside: +245.91%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $22.59
Upside: -38.03%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.48
Upside: +458.04%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $15.60
Upside: +316.67%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.66
Upside: +76.68%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $6.20
Upside: +2,351.61%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $19.58
Upside: +83.86%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.41
Upside: +14,541.29%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $2.12
Upside: +255,219.15%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.13
Upside: +251.44%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $4.30
Upside: +318.60%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $6.83
Upside: +632.06%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.46
Upside: +221,817.81%